1. Moyle, G.J.; Back, D. Principles and Practice of HIV-protease Inhibitor Pharmacoenhancement. HIV Med. 2001, 2, 105-113.

2. ABDA Database Ver. 3.2.1. Apotheken Dienstleistungsgesellschaft, Eschborn, FRG; Status: January 2001.

3. Krayenbühl, J.C; Vozeh, S.; Kondo-Oestreicher, M.; Dayer, P. Drug-Drug Interactions of New Active Substances: Mibefradil Example. Eur. J. Clin. Pharmacol. 1999, 53, 559-565.

4. Dresser, G.K.; Spence, J.D.; Bailey, D.G. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition. Clin. Pharmacokinet. 2000, 38, 41-57.

5. Kanamitsu, S.-L; Ito, K.; Okuda, H.; Ogura, K.; Watabe, T.; Muro, K.; Sugiyama, Y. Prediction of in vivo Drug-Drug Interactions Based on Mechanism-based Inhibition from in vitro Data: Inhibition of 5-Fluorouracil Metabolism by (E)-5-(2-Bromovinyl)uracil. Drug Metab. Disp. 2000, 28, 467-474.

6. Schoolar Reynolds, K. Decision Points for Requiring an in vivo Study. 7th EUFEPS Conference on Optimising Drug Development: Strategies to Assess Drug Metabolism/Transport Interaction Potential—Towards a Consensus, Basel (2000).

7. Ito, K.; Iwatsubo, T.; Kanamitsu, S.; Ueda, K.; Suzuki, H.; Sugiyama, Y. Prediction of Pharmacokinetic Alterations Caused by Drug-Drug Interactions: Metabolic Interaction in the Liver. Pharmacol. Rev. 1998, 50, 387-411.

8. Kohl, C; Steinkellner, M. Prediction of Pharmacokinetic Drug/Drug Interactions from in vitro Data: Interactions of the Nonsteroidal Anti-inflammatory Drug Lornoxicam with Oral Anticoagulants. Drug Metab. Disp. 2000, 28, 161168.

9. Bertz, R.J.; Granneman, G.R. Use of in vitro and in vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions. Clin. Pharmacokinet. 1997, 32, 210-258.

10. Abdel-Rahman, S.; Leeder, J. Phenobarbital, Phenytoin and Carbamazepine. Metabolic Drug Interactions, Levy, R.; Thummel, K.; Trager, W.; Hansten, P.; Eichelbaum, M., Eds.; Lippincott, Williams and Wilkins: Philadelphia, Pa, 2000; 673-690.

11. Jang, G.; Maurel, P. Rifampin, Dexamethasone and Omeprazole. Metabolic Drug Interactions, Levy, R.; Thummel, K.; Trager, W.; Hansten, P.; Eichelbaum, M., Eds.; Lippincott, Williams and Wilkins: Philadelphia, Pa, 2000; 691-706.

12. Slattery, J. Isoniazid and Ethanol. Metabolic Drug Interactions, Levy, R.; Thummel, K.; Trager, W.; Hansten, P.; Eichelbaum, M., Lippincott, Eds.; Williams and Wilkins: Philadelphia, Pa, 2000; 691-706.


14. Tucker, J.T.; Houston, J.B.; Huang, S.-M. Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Towards a Consensus. Br. J. Clin. Pharmacol. 2001, 52, 107-117.

15. Ziegler, V.E.; Biggs, J.T.; Tricyclic Plasma Levels: Effect of Age, Race, Sex and Smoking. JAMA 1977, 238, 2167-2169.

16. Altice, F.L.; Friedland, G.H.; Cooney, E.L. Nevirapine Induced Opiate Withdrawal Among Injection Drug Users with HIV Infection Receiving Methadone. AIDS 1999, 13, 957-962.

17. Kreek, M.J.; Garfield, J.W.; Gutjahr, C.L. Rifampin-Induced Methadone Withdrawal. N. Engl. J. Med. 1976, 294, 1104-1106.

18. Fattore, C.; Cipolla, G.; Gatti, G. Induction of Ethinylestradiol and Levonorgestrel Metabolism by Oxcarbazepine in Healthy Women. Epilepsia 1999, 40, 783787.

19. Timmer, C.J.; Sitsen, J.M.; Delbressine, L.P. Clinical Pharmacokinetics of Mirtazapine. Clin. Pharmacokinet. 2000, 38, 461-474.

20. Piscitelli, S.C.; Burstein, A.H.; Chaitt, D.; Alfaro, R.M.; Falloon, J. Indinavir Concentrations and St. John's Wort. Lancet 2000, 355 (9203), 547-548.

21. Mai, L; Kruger, H.; Budde, K.; Johne, A.; Brockmoller, J.; Neumayer, H.H.; Roots, I. Hazardous Pharmacokinetic Interaction of Saint John's Wort (Hypericum perforatum) with the Immunosuppressant Cyclosporin. Int. J. Clin. Pharmacol. Ther. 2000, 38, 500-502.

22. Johne, A.; Brockmoller, J.; Bauer, S.; Maurer, A.; Langheinrich, M.; Roots, I. Pharmacokinetic Interaction of Digoxin with an Herbal Extract from St. John's Wort (Hypericum perforatum). Clin. Pharmacol. Ther. 1999, 66, 338-345.

23. Vore, M. Phase III Elimination: Another Two-edged Sword. Environ. Health Perspect. 1994, 102, 422-423.

24. Venter, J.C.; Adams, M.D.; Myers, E.W.; Li, P.W., et al. The Sequence of the Human Genome. Science 2001, 291, 1304-1351.

25. Povey, S.; Lovering, R.; Bruford, E.; Wright, M.; Lush, M.; Wain, H. The HUGO Gene Nomenclature Committee (HGNC). Hum. Genet. 2001, 109, 678-680.

26. White, J.A.; McAlpine, P.J.; Antonarakis, S.; Cann, H.; Eppig, J.T.; Frazer, K.; Frezal, J.; Lancet, D.; Nahmias, J.; Pearson, P.; Peters, J.; Scott, A.; Scott, H.; Spurr, N.; Talbot, Jr. C.; Povey, S. Guidelines for Human Gene Nomenclature. Genomics 1997, 45, 468-471.

27. Ito, S. Transplacental Treatment of Fetal Tachycardia: Implications of Drug Transporting Proteins in Placenta. Semin. Perinatol. 2001, 25, 196-201.

28. Utoguchi, N.; Audus, K. Carrier-mediated Transport of Valproic Acid in BeWo Cells, a Human Trophoblast Cell Line. Int. J. Pharm. 2000 Feb 15, 195 (1-2), 115-24.

29. Ganapathy, V.; Prasad, P.D.; Ganapathy, M.E.; Leibach, F.H. Placental Transporters Relevant to Drug Distribution Across the Maternal-Fetal Interface. J. Pharmacol. Exp. Ther. 2000, 294, 413-420.

30. Wu, C.Y.; Benet, I.Z.; Hebert, M.F.; Gupta, S.K.; Rowland, M.; Gomez, D.Y.; Wacher, V.J. Differentiation of Absorption and First-pass Gut and Hepatic Metabolism in Humans: Studies with Cyclosporine. Clin. Pharmacol. Ther. 1995, 58, 492-497.

31. Spahn-Langguth, H.; Baktir, G.; Radschuweit, A.; Okyar, A.; Terhaag, B.; Ader, P.; Hanafy, A.; Langguth, P. P-glycoprotein Transporters and the Gastrointestinal Tract: Evaluation of the Potential in vivo Relevance of in vitro Data Employing Talinolol as Model Compound. Int. J. Clin. Pharmacol. Ther. 1998, 36 (1), 16-24.

32. Gramatte, T.; Oertel, R. Intestinal Secretion of Intravenous Talinolol is Inhibited by Luminal R-verapamil. Clin. Pharmacol. Ther. 1999, 66, 239-245.

33. Schwarz, U.I.; Gramatte, T.; Krappweis, J.; Oertel, R.; Kirch, W. P-glycoprotein Inhibitor Erythromycin Increases Oral Bioavailability of Talinolol in Humans. Int. J. Clin. Pharmacol. Ther. 2000, 38 (4), 161-167.

34. Hanafy, A. Transport Inhibition and Induction as Sources for Absorption and Disposition-related Drug-Drug Interaction: Talinolol as Model Substrate for the ABC-transporter P-glycoprotein. PhD Thesis, Department of Pharmacy, Martin-Luther-University Halle-Wittenberg, 2001.

35. Wagner, D.; Spahn-Langguth, H.; Hanafy, A.; Koggel, A.; Langguth, P. Intestinal Drug Efflux: Formulation and Food Effects. Adv. Drug Deliv. Rev. 50 Suppl. 1, S13-S31.

36. Dresser, G.K.; Bailey, D.G.; Leake, B.F.; Schwarz, U.I.; Dawson, P.A.; Freeman, D.J.; Kim, R.B. Fruit Juices Inhibit Organic Anion Transporting Polypeptide-mediated Drug Uptake to Decrease the Oral Availability of Fexofenadine. Clin. Pharmacol. Ther. 2002, 71, 11-20.

37. Westphal, K.; Weinbrenner, A.; Giessmann, T.; Stuhr, M.; Franke, G.; Zschiesche, M.; Oertel, R.; Terhaag, B.; Kroemer, H.K.; Siegmund, W. Oral Bioavailability of Digoxin is Enhanced by Talinolol: Evidence for Involvement of Intestinal P-glycoprotein. Clin. Pharmacol. Ther. 2000, 68, 6-12.

38. Sababi, M.; Borga, O.; Hultkvist-Bengtsson, U. The Role of P-glycoprotein in Limiting Intestinal Regional Absorption of Digoxin in Rats. Eur. J. Pharm. Sci. 2001, 14, 21-27.

39. Woodland, C; Verjee, Z.; Giesbrecht, E.; Koren, G.; Ito, S. The Digoxin-Propafenone Interaction: Characterization of a Mechanism Using Renal Tubular Cell Monolayers. J. Pharmacol. Exp. Ther. 1997, 283, 39-45.

40. Ito, S.; Woodland, C.; Harper, P.A.; Koren, G. The Mechanism of the Verapamil-Digoxin Interaction in Renal Tubular Cells (LLC-PK1). Life Sci. 1993, 53, 399403.

41. Verschraagen, M.; Koks, C.H.; Schellens, J.H.; Beijnen, J.H. P-glycoprotein System as a Determinant of Drug Interactions: The Case of Digoxin-Verapamil. Pharmacol. Res. 1999, 40, 301-306.

42. Su, S.F.; Huang, J.D. Inhibition of the Intestinal Digoxin Absorption and Exsorption by Quinidine. Drug Metab. Dispos. 1996, 24, 142-147.

43. Jalava, K.M.; Partanen, J.; Neuvonen, P.J. Itraconazole Decreases Renal Clearance of Digoxin. Ther. Drug Monit. 1997, 19, 609-613.

44. Salphati, L.; Benet, L.Z. Effects of Ketoconazole on Digoxin Absorption and Disposition in Rat. Pharmacology 1998, 56, 308-313.

45. Wakasugi, H.; Yano, I.; Ito, T.; Hashida, T.; Futami, T.; Nohara, R.; Sasayama, S.; Inui, K. Effect of Clarithromycin on Renal Excretion of Digoxin: Interaction with P-glycoprotein. Clin. Pharmacol. Ther. 1998, 64, 123-128.

46. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H.P.; von Richter, O.; Zundler, J.; Kroemer, H.K. The Role of Intestinal P-glycoprotein in the Interaction of Digoxin and Rifampin. J. Clin. Invest. 1999, 104, 147-153.

47. Kovarik, J.M.; Rigaudy, L.; Guerret, M.; Gerbeau, C.; Rost, K.L. Longitudinal Assessment of a P-glycoprotein-mediated Drug Interaction of Valspodar on Digoxin. Clin. Pharmacol. Ther. 1999, 66, 391-400.

48. Boyd, R.A.; Stern, R.H.; Stewart, B.H.; Wu, X.; Reyner, E.L.; Zegarac, E. A.; Randinitis, E.J.; Whitfield, L. Atorvastatin Coadministration may Increase Digoxin Concentrations by Inhibition of Intestinal P-glycoprotein-mediated Secretion. J. Clin. Pharmacol. 2000, 40, 91-98.

49. Johne, A.; Brockmoller, J.; Bauer, S.; Maurer, A.; Langheinrich, M.; Roots, I. Pharmacokinetic Interaction of Digoxin with an Herbal Extract from St. John's Wort (Hypericum perforatum). Clin. Pharmacol. Ther. 1999, 66 (4), 338345.

50. Fromm, M.F.; Kim, R.B.; Stein, C.M.; Wilkinson, G.R.; Roden, D.M. Inhibition of P-glycoprotein-mediated Drug Transport: A Unifying Mechanism to Explain the Interaction Between Digoxin and Quinidine. Circulation 1999, 99, 552-557.

51. Ayrton, A.; Morgan, P. Role of Transport Proteins in Drug Absorption, Distribution and Excretion. Xenobiotica 2001, 31, 469-497.

52. Ushigome, F.; Takanaga, H.; Matsuo, H.; Yanai, S.; Tsukimori, K.; Nakano, H.; Uchiumi, T.; Nakamura, T.; Kuwano, M.; Ohtani, H.; Sawada, Y. Human Placental Transport of Vinblastine, Vincristine, Digoxin and Progesterone: Contribution of P-glycoprotein. Eur. J. Pharmacol. 2000, 408, 1-10.

53. Pauli-Magnus, C.; Mürdter, T.; Godel, A.; Mettang, T.; Eichelbaum, M.; Klotz, U.; Fromm, M.F. P-glycoprotein-mediated Transport of Digitoxin, a-Methyldigoxin and ß-Acetyldigoxin. Naunyn-Schmiedeberg's Arch. Pharmacol. 2001, 363, 337-343.

54. Flanagan, S.D.; Benet, L.Z. Net Secretion of Furosemide is Subject to Indomethacin Inhibition, as Observed in Caco-2 Monolayers and Excised Rat Jejunum. Pharm. Res. 1999, 16, 221-224.

55. Smith, D.E.; Brater, D.C.; Lin, E.; Benet, L.Z. Attenuation of Furosemid's Pharmacokinetic Effect by Indomethacin: Pharmacokinetic Evaluation. J. Pharmacokin. Biopharm. 1979, 7, 265-274.

56. Chennavasin, P.; Seiwell, R.; Brater, D.C. Pharmacokinetic-Dynamic Analysis of the Indomethacin-Furosemide Interaction in Man. J. Pharmacol. Exp. Ther. 1980, 215, 77-81.

57. Ito, S. Drug Secretion Systems in Renal Tubular Cells: Functional Models and Molecular Identity. Pediatr. Nephrol. 1999, 13, 980-988.

58. Rolling, M.V.; Pui, C.H.; Sandlund, J.T.; Rivera, G.K.; Hancock, M.L.; Boyett, J.M.; Schuetz, E.G.; Evans, W.E. Adverse Effect of Anticonvulsants on Efficacy of Chemotherapy for Acute Lymphoblastic Leukaemia. Lancet 2000, 356, 285290.

59. Schuetz, E.; Strom, S. Promiscuous Regulator of Xenobiotic Removal. Nature Medicine 2001, 7, 536-537.

60. Synold, T.W.; Dussault, I.; Forman, B.M. The Orphan Nuclear Receptor SXR Coordinately Regulates Drug Metabolism and Efflux. Nature Medicine 2001, 7, 584-590.

61. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H.P.; Brockmöller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional Polymorphisms of the Human Multidrug-resistance Gene: Multiple Sequence Variations and Correlation of One Allele with P-glycoprotein Expression and Activity in vivo. PNAS 2000, 97, 3473-3478.

62. Sakaeda, T.; Nakamura, T.; Horinouchi, M.; Kakumoto, M.; Ohmoto, N.; Sakai, T.; Morita, Y.; Tamura, T.; Aoyama, N.; Hirai, M.; Kasuga, M.; Okumura, K. MDR1 Genotype-related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects. Pharm. Res. 2001, 18, 1400-1404.

63. Kim, R.B.; Leake, B.F.; Choo, E.F.; Dresser, G.K.; Kubba, S.V.; Schwarz, U. L; Taylor, A.; Xie, H.-G.; McKinsey, J.; Zhou, S.; Lan, L.-B.; Schuetz, J. D.; Schuetz, E.G.; Wilkinson, G.R. Identification of Functionally Variant MDR1 Alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001, 70, 189-199.

64. Schaeffeler, E.; Eichelbaum, M.; Brinkmann, U.; Penger, A.; Asante-Poku, S.; Zanger, U.M.; Schwab, M. Frequency of C3435T Polymorphism of MDR1 Gene in African People. Lancet 2001, 358, 383-384.

65. Fellay, J.; Marzolini, C; Meaden, E.R.; Back, D.J.; Buclin, T.; Chave, J.-P.; Decosterd, L.A.; Furrer, H.; Opravil, M.; Pantaleo, G.; Retelska, D.; Ruiz, L.; Schinkel, A.H.; Vernazza, P.; Eap, C.B.; Telenti, A. Response to Antiretroviral Treatment in HIV-1-Infected Individuals with Allelic Variants of the Multidrug Resistance Transporter 1: A Pharmacogenetics Study. Lancet 2002, 359, 30-36.

66. Kerb, R.; Hoffmeyer, S.; Brinkmann, U. ABC Drug Transporters: Hereditary Polymorphisms and Pharmacological Impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001, 2, 51-64.

67. Conrad, S.; Kauffmann, H.M.; Ito, K.; Deeley, R.G.; Cole, S.P.; Schrenk, D. Identification of Human Multidrug Resistance Protein 1 (MRP1) Mutations and Characterization of a G671V Substitution. J. Hum. Genet. 2001, 46, 656663.

68. Cavet, M.E.; West, M.; Simmons, N.L. Transport and Epithelial Secretion of the Cardiac Glycoside, Digoxin, by Human Intestinal Epithelial (Caco-2) Cells. Br. J. Pharmacol. 1996, 118, 1389-1396.

69. Drescher, S.; Glaeser, H.; Hitzl, M.; Herrlinger, H.; van der Kuip, H.; Eichelbaum, M. Direct Intestinal Excretion is an Important Route of Digoxin Elimination in Humans (Abstract). Eur. J. Clin. Pharmacol. 2000, 56, A16.

70. Manninen, V.; Apajalahti, A.; Melin, J.; Karesoja, M. Altered Absorption of Digoxin in Patients Given Propantheline and Metoclopramide. Lancet 1973, 1, 398-400.

71. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H.P.; von Richter, O.; Zundler, J.; Kroemer, H.K. The Role of Intestinal P-glycoprotein in the Interaction of Digoxin and Rifampin. J. Clin. Invest. 1999, 104 (2), 147-153.

72. Hilgendorf, C.; Langguth, P.; Koggel, A.; Regardh, C.G.; Spahn-Langguth, H. Identification of Transporters Involved in the Intestinal Secretion of Selected Adrenoceptor Antagonists in Caco-2 Cells: Relevance of P-glycoprotein and the Organic Cation Transporter. Pharm. Res. (submitted) 2000.

73. Cvetkovic, M.; Leake, B.; Fromm, M.F.; Wilkinson, G.; Kim, R.B. OATP and P-glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine. Drug Metab. Dispos. 1999, 27, 866-871.

74. Russell, T.; Stoltz, M.; Weir, S. Pharmacokinetics, Pharmacodynamics, and Tolerance of Single- and Multiple-dose Fexofenadine Hydrochloride in Healthy Male Volunteers. Clin. Pharmacol. Ther. 1998, 64, 612-621.

75. Beaumont—personal communication.

76. Rowland, M.; Tozer, T. Clinical Pharmacokinetics, 3rd Ed.; Williams & Wilkins, 1995.

77. Mattson, R.H.; Cramer, J.A.; Williamson, P.D.; Novelly, R.A. Valproic Acid in Epilepsy: Clinical and Pharmacological Effects. Ann. Neurol. 1978, 3, 20-25.

78. Rolan, P.E. Plasma Protein Binding Displacement Interactions—Why Are They Still Regarded as Clinically Important? Br. J. Clin. Pharmac. 1994, 37, 125-128.

79. Lai, M.L.; Huang, J.D. Dual Effect of Valproic Acid on the Pharmacokinetics of Phenytoin. Biopharm. Drug Dispos. 1993, 14, 365-370.

80. Perucca, E.; Hebdige, S.; Frigo, G.M.; Gatti, G.; Lecchini, S.; Crema, A. Interaction Between Phenytoin and Valproic Acid: Plasma Protein Binding and Metabolic Effects. Clin. Pharmacol. Ther. 1980, 28, 779-789.

81. Sweeney, K.R.; Chapron, D.J.; Brandt, J.L.; Gomolin, I.H.; Feig, P.U.; Kramer, P.A. Toxic Interaction Between Acetazolamide and Salicylate: Case Reports and a Pharmacokinetic Explanation. Clin. Pharmacol. Ther. 1986, 40, 518-524.

82. Sansom, L.N.; Evans, A.M. What is the True Clinical Significance of Plasma Protein Binding Displacement Interactions? Drug Safety 1995, 12, 227-233.

83. Benmoussa, K.; Sabouraud, A.; Scherrmann, J.M.; Brossard, D.; Bourre, J. M. Effect of Fat Substitutes, Sucrose Polyester and Tricarballylate Triester, on Digitoxin Absorption in the Rat. J. Pharm. Pharmacol. 1993, 45, 692696.

84. Benmoussa, K.; Sabouraud, A.; Scherrmann, J.M.; Bourre, J.M. Cyclosporin Absorption is Impaired by the Fat Substitutes, Sucrose Polyester and Tricaarballylate Triester, in the Rat. Pharm. Res. 1994, 10, 1458-1461.

85. Geusau, A.; Tschachler, E.; Meixner, M.; Sandermann, S.; Papke, O.; Wolf, C; Valic, E.; Stingl, G.; McLachlan, M. Olestra Increases Faecal Excretion of 2,3,7,8-Tetrachlorodibenzo-p-digoxin. Lancet 354, 1266-1267.

86. Moser, G.A.; McLachlan, M.S. A Non-absorbable Dietary Fat Substitute Enhances Elimination of Persistent Lipophilic Contaminants in Humans. Chemosphere

1999, 39, 1513-1521.

87. Miller, K.W.; Williams, D.S.; Carter, S.B.; Jones, M.B.; Mishell, D.R., Jr. The Effect of Olestra on Systemic Levels of Oral Contraceptives. Clin. Pharmacol. Ther. 1990, 48, 34-40.

88. Roberts, R.J.; Leff, R.D. Influence of Absorbable and Nonabsorbable Lipids and Lipidlike Substances on Drug Bioavailability. Clin. Pharmacol. Ther. 1989, 45, 299-304.

89. Dollery, C. Therapeutic Drugs, 2nd Ed.; Churchill Livingstone: Edinburgh, 1999.

90. Narchi, P.; Edouard, D.; Bourget, P.; Otz, J., Cattaneo, I. Gastric Fluid pH and Volume in Gynaecologic Out-patients. Influences of Cimetidine and Cimetidine-Sodium Citrate Combination. Eur. J. Anaesthesiol. 1993, 10, 357-361.

91. Van der Meer, J.W.M.; Keuning, J.J.; Scheijgrond, H.W.; Heykants, J.; van Cutsem, J.; Brugmans, J. The Influence of Gastric Acidity on the Bioavailability of Ketoconazole. J. Antimicrob. Chemotherapy 6, 552-554.

92. Bowdle, T.A.; Freund, P.R.; Slattery, J.T. Propranolol Reduces Bupivacaine Clearance. Anesthesiology 1987, 66, 36-38.

93. Gawronska-Szklarz, G.; Bijos, P.; Feszak, J.; Drozdzik, M.; Goertz, K.; Wojcicki, J. Effect of Propranolol on Lidocaine Pharmacokinetics. Pol. Tyg. Lek. 1990, 45 (23-24), 473-475.

94. Wood, M. Pharmacokinetic Drug Interactions in Anaesthetic Practice. Clin. Pharmacokinet. 1991, 21, 285-307.

95. FDA Guidance for Industry: in vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis and Recommendations for Dosing and Labeling. Rockville (MD): US Department of Health and Human Services. Public Health Service, Food and Drug Administration, 1999.

96. In vivo Drug-Drug Interaction Studies—A Survey of all New Molecular Entities Approved from 1987-1997. Marroum, P.J.; Uppoor, R.; Parmelee, T.; Ajayi, F.; Burnett, A.; Yuan, R.; Svadjian, R.; Lesko, L.; Balian, J.; Clin. Pharmacol. Ther.

97. Bartkowski, R.R.; Goldberg, M.E.; Larijani, G.E.; Boerner, T. Inhibition of Alfentanil Metabolism by Erythromycin. Clin. Pharmcol. Ther. 1989, 46, 99102.

98. Note for Guidance on the Investigation of Drug Interactions, the European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, London, 1997.

99. Therapeutic Products Programme Guidance Document, Drug-Drug Interactions: Studies in vitro and in vivo, Health Canada, 2001.

100. FDA Guidance for Industry: Population Pharmacokinetics. Rockville (MD): US Department of Health and Human Services, Public Health Service, Food and Drug Administration, 1999.

101. Samara, E.; Granneman, R. Role of Population Pharmacokinetics in Drug Development a Pharmaceutical Industry Perspective. Clin. Pharmacokinet. 1997, 32 (4), 294-312.

102. Huang, S.M.; Honig, P.; Lesko, L.; Temple, R.; Williams, R. An Integrated Approach to Assessing Drug-Drug Interactions: A Regulatory Perspective. Drug-Drug Interactions, Rodrigues, A.D., Ed.; Marcel Decker: New York, 2001, 605-632.

Was this article helpful?

0 0

Post a comment